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Abstract
Background: Radiomicrosphere therapy (RT) utilizing yttrium-90 (90Y) microspheres has been
shown to be an effective regional treatment for primary and secondary hepatic malignancies. We
sought to determine a large academic institution's experience regarding the extent and frequency
of gastrointestinal complications.
Methods: Between 2004 and 2007, 27 patients underwent RT for primary or secondary hepatic
malignancies. Charts were subsequently reviewed to determine the incidence and severity of GI
ulceration.
Results: Three patients presented with gastrointestinal bleeding and underwent upper endoscopy.
Review of the pretreatment angiograms showed normal vascular anatomy in one patient, sclerosed
hepatic vasculature in a patient who had undergone prior chemoembolization in a second, and an
aberrant left hepatic artery in a third. None had undergone prophylactic gastroduodenal artery
embolization. Endoscopic findings included erythema, mucosal erosions, and large gastric ulcers.
Microspheres were visible on endoscopic biopsy. In two patients, gastric ulcers were persistent at
the time of repeat endoscopy 1–4 months later despite proton pump inhibitor therapy. One elderly
patient who refused surgical intervention died from recurrent hemorrhage.
Conclusion: Gastrointestinal ulceration is a known yet rarely reported complication of 90Y
microsphere embolization with potentially life-threatening consequences. Once diagnosed,
refractory ulcers should be considered for aggressive surgical management.
Background
The incidence of hepatocellular carcinoma continues to
increase in the United States [1,2] resulting in increased
patient encounters for management decisions. Further-
more, the continued underutilization of recommended
cancer screening strategies [3] results in patients diag-
nosed with advanced stages of cancer [4] which can
include liver metastases. Several novel medical and surgi-
cal approaches are available to treat these tumors when
unresectable. One such treatment strategy is radioembol-
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with 90Y microsphere radioembolization.
This radioembolization technique consists of glass
(TheraSpheres®, MDS Nordion Inc., Ottawa, ON) or resin
(SIR-Spheres®, Sirtex Medical Inc., Wilmington, MA)
microspheres 20–40 micrometers in size which are
embedded with radioactive 90Y [5]. Such regional therapy
takes advantage of the dual blood supply of the liver.
Whereas normal liver parenchyma is supplied principally
by the portal system [6], the majority of hepatic tumors
derive their blood supply from the hepatic artery [7]. As
such, the microspheres are selectively injected into the
hepatic artery circulation and on to the tumor's micros-
vasculature where they embolize. As 90Y degrades, the
microspheres emit beta-radiation (mean energy 0.93
MeV, maximum energy 2.27 MeV) to an average depth of
2.4 mm localized at the tumor site [8] so as to minimize
damage to the surrounding parenchyma. The half life of
90Y is 64.1 hours.
While the overall complication rate of the procedure is
low [9], gastric and duodenal ulceration after 90Y radi-
oembolization has been described [8,10-13]. Gastrointes-
tinal ulceration is most commonly a result of
arterioarterial non-target flow of the microspheres
through an aberrant hepatic arterial vasculature supplying
the stomach and duodenum [12] with resultant radiation
damage to the affected mucosa [8].
We sought to determine the frequency of clinically rele-
vant gastrointestinal ulceration as a complication of 90Y
radioembolization at our institution. Furthermore, we
sought to describe each patient's clinical course in an
attempt to establish common presenting signs and symp-
toms, as well as best treatment approaches.
Methods
Our experience with RT began in mid-2004. Since then,
we have utilized RT for primary and secondary hepatic
malignancies not amenable to curative resection and/or
refractory to systemic chemotherapy. We reviewed the
charts of all patients undergoing RT in our early experi-
ence from 2004 through 2007. All patients underwent
pretreatment celiac angiography to detect the hepatic arte-
rial distribution of the tumor. The gastroduodenal artery
was not empirically embolized as patients were to have
selective right or left hepatic arterial delivery of the 90Y
microspheres (SIR-Spheres®, Sirtex Medical Inc., Wilming-
ton MA) However, if angiography demonstrated vessels at
high risk for non-target flow, these were embolized prior
to RT. Extrahepatic shunting was evaluated using infusion
of Technetium-99 labeled macroagreggated albumin
(MAA) at the precise site chosen for future RT. A catheter
was placed in the right or left hepatic artery. 4 mCi of
Technetium-99 labeled macroaggregated albumin were
instilled via the implanted catheter. Planar images were
then obtained of the lungs and abdomen to quantify the
degree of extrahepatic activity i.e. shunting away from the
liver lesion. Patients with less than ten percent pulmonary
shunting were considered good candidates for RT using
full dose of 90Y by dosimetry according to the manufac-
turer's recommendations. Those with 10–20% pulmo-
nary shunting underwent RT with decreased 90Y dosing.
Patients with greater than 20% percent pulmonary shunt-
ing were considered unsuitable for RT. Within four weeks,
90Y microspheres were infused at the exact location as the
MAA study. All patients underwent immediate single pho-
ton emission computed tomography (SPECT) imaging to
determine the distribution of 90Y. Patients were moni-
tored for six hours and discharged the following day on a
steroid taper and proton pump inhibitor.
A retrospective chart review of all patients presenting for
upper endoscopy after RT utilizing 90Y microspheres was
performed. The need for an endoscopic evaluation was
determined by the treating physician. If a patient was
determined to have undergone an upper endoscopy after
RT their chart was reviewed further for clinical informa-
tion. We specifically sought to determine presenting signs
and symptoms, endoscopic findings, pathology specimen
reports, and clinical outcomes. The study was approved by
the cancer IRB of Ohio State University.
Results
Twenty-seven patients underwent 33 treatments with RT
for colorectal metastases (N = 15), hepatocellular carci-
noma (N = 4), cholangiocarcinoma metastases (N = 2),
neuroendocrine metastases (N = 2), unknown primary
metastases (N = 2), prostate carcinoma metastases (N =
1), and melanoma metastases (N = 1). The median fol-
low-up from time of RT was 6 months (mean 9.7 months;
range 1–48 months). One patient was lost to follow-up
after the procedure. Three patients presented with gas-
trointestinal ulceration.
The first patient had moderately differentiated rectal ade-
nocarcinoma metastatic to the liver. Despite aggressive
cytotoxic chemotherapy his cancer progressed and the
liver lesions became increasingly symptomatic with par-
tial biliary obstruction. RT utilizing 90Y microspheres was
determined to be the optimal treatment modality based
on local expertise. Pre-RT Technetium-99 MAA showed
less than 10% shunting to the lung. Pre-procedural angi-
ography showed normal caliber vessels with the common
hepatic artery trifurcating into the right hepatic artery, the
left hepatic artery, and the gastroduodenal artery. The left
gastric artery did not communicate with the hepatic circu-
lation. However, the left hepatic artery trunk aberrantly
arose from the common hepatic artery five millimetersPage 2 of 6
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bifurcated one centimeter distal to its origin. The patient
then received 1.5 GBq of 90Y microspheres via the right
hepatic artery. Due to successful treatment with RT in the
right hepatic lobe, this modality was employed for the left
liver lobe lesions four months later. Normal vascular anat-
omy was confirmed with repeat angiography. 1.5 GBq of
90Y microspheres were placed in the left hepatic artery
with angiographic evidence of decrease in antegrade flow.
After each RT session, no evidence of extrahepatic 90Y dep-
osition was seen on post-RT SPECT imaging. The patient
presented 16 weeks later with a three day history of
abdominal pain, nausea, and melena. Esophagogastrodu-
odenoscopy was undertaken demonstrating erythema of
the duodenal bulb and a large gastric body ulcer with a
clean base (figure 1). The patient was not taking non-ster-
oidal anti-inflammatory medications and Helicobacter
pylori infection was not suspected although this was not
specifically tested for. Biopsies were not obtained but
given the lack of concomitant risk factors, complication of
RT was suspected. Despite aggressive ongoing therapy
with proton pump inhibitors the patient had ongoing
blood loss. Gastrectomy was recommended but the
patient refused further medical and surgical intervention
and expired.
The second patient had moderately differentiated adeno-
carcinoma of the colon originally treated by right hemi-
colectomy in 1994. Three years after the original diagnosis
he was found to have multiple hepatic metastases and was
treated with a course of 5-FU based chemotherapy.
Despite aggressive medical therapy, re-staging imaging
studies showed a remaining lesion in segment six. He
underwent margin-negative non-anatomic resection of
the solitary tumor and no other lesions were observed on
intraoperative ultrasound. In 2000 he was again found to
have recurrent disease in regions of margin-negative non-
anatomic resection hepatic segments 4, 5, and 8. He was
treated with a combination of radiofrequency ablation
(RFA) and surgical resection of all disease. He again had
intraoperative RFA to new lesions in the right liver in
2003. Right and left hepatic artery bland embolization
was subsequently completed two months after his last
operation. The patient again had cancer recurrence in his
liver in 2005 and was recommended for RT. At the time of
pretreatment angiography, a replaced left hepatic artery
arising from the left gastric artery and several areas of nar-
rowing in the intra-hepatic portion of the hepatic artery
was seen. Prophylactic embolization of the gastroduode-
nal artery was completed as collateral flow to the liver sup-
plied from this vessel was also identified angiographically.
His MAA study confirmed that he had no extrahepatic
shunting. One month later 1.61 GBq of 90Y microspheres
was administered via the right hepatic artery. Post-treat-
ment SPECT showed no extrahepatic uptake. The patient
developed epigastric pain which was evaluated by upper
endoscopy one month after RT. The patient was found to
have a cratered gastric ulceration without bleeding at the
pylorus (figure 2). No biopsies were obtained as the
patient was on anticoagulant therapy. The patient was dis-
charged on proton pump inhibitor therapy twice daily.
The patient continued to have abdominal pain not
relieved by acid suppressant medications and repeat
endoscopy was undertaken six weeks later. Endoscopy
showed a persistent non-healing ulcer in the pylorus and
an additional cratered ulcer in the antrum. The patient
was instructed to hold anticoagulants and biopsies of the
non-healing ulcers were obtained on two separate occa-
sions over the ensuing three months. Pathology from
both specimens showed foreign material and microscopic
spherules (figure 3) consistent with the patient's known
history of 90Y therapy. The withdrawal of anti-coagulation
and the continued acid suppression resulted in stabiliza-
tion of the patient's hemoglobin and his symptoms
resolved. The patient ultimately developed extrahepatic
recurrence and expired from complications of metastatic
disease.
The third patient had adenocarcinoma from an unknown
primary metastatic to the right lobe of the liver. She sub-
sequently underwent mesenteric angiography to evaluate
her candidacy for 90Y RT. The patient demonstrated nor-
mal hepatic arterial anatomy including the right hepatic
arterial target. There was no abnormal communication of
Endoscopic view of a large gastric body ulcerFigure 1
Endoscopic view of a large gastric body ulcer.Page 3 of 6
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tium-99 MAA demonstrated a 5% shunt fraction to the
lungs. In a second procedure, she received 1.9 GBq 90Y RT
delivered selectively to the right hepatic artery. Stagnation
of blood flow was witnessed at the conclusion of the pro-
cedure. Post-infusion scintigraphy demonstrated no radi-
opharmaceutical uptake outside the liver. The patient
subsequently developed melena five months after RT.
Upper endoscopy demonstrated friability and granularity
in the duodenal bulb as well as the second portion of the
duodenum and the gastric antrum (figure 4). There was a
sharp demarcation of abnormal to normal mucosa in the
second portion of the duodenum. Biopsies were obtained
and demonstrated foreign body spherules in the gastric as
well as the duodenal specimens consistent with 90Y ther-
apy. Helicobacter pylori was not demonstrated on antral
biopsies. Despite continued therapy with proton pump
inhibitors, the patient continued to demonstrate gastroin-
testinal hemorrhage. The patient ultimately underwent
empiric embolization of her gastroduodenal artery (GDA)
starting at the proximal gastroepiploic artery. A combina-
tion of coils and gel foam was used to achieve successful
embolization. Despite embolization of her GDA, the
patient continued to have gastrointestinal hemorrhage.
Consequently, she underwent repeat angiography with
embolization of two small antral branches off of the left
gastric artery resulting in hemostasis. However, repeat
endoscopy seven months after 90Y radiotherapy demon-
strated active bleeding from the duodenal erythema
requiring epinephrine injection and argon plasma coagu-
lation for hemostasis. Despite aggressive endoscopic ther-
apy the patient continued to have transfusion requiring
mucosal hemorrhage. Selective bland embolization of
multiple left gastric artery branches was completed and
her hemoglobin remained stable thereafter. The patient
subsequently developed rapid progression of her cancer
Endoscopic view of a pyloric channel ulcerFigure 2
Endoscopic view of a pyloric channel ulcer.
Hematoxylin and Eosin stain of gastric biopsy specimen (400×)Figure 3
Hematoxylin and Eosin stain of gastric biopsy speci-
men (400×). Note microspheres in gastric mucosa.
Endoscopic view of antral erosions and erythemaFigure 4
Endoscopic view of antral erosions and erythema.Page 4 of 6
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metastatic disease. At the time of her death she did not
have evidence of gastrointestinal hemorrhage.
Discussion
In our experience, three of twenty-seven (11.1%) patients
presented with endoscopically confirmed gastrointestinal
ulceration/mucosal disruption. These all occurred in our
first twelve cases and no changes occurred in our proce-
dural technique during the time period studied to account
for these complications. Although we have not seen any
further incidents of gastrointestinal ulceration as we have
gained more experience, this is possibly an underestima-
tion as patients frequently present with non-specific
abdominal complaints that may be indicative of gastroin-
testinal tract ulceration similar to our patients. All three of
our patients presented with abdominal pain and nausea.
Two of the three presented with melena. As such, clini-
cians should employ a low threshold for endoscopic eval-
uation and treatment in a patient following RT therapy
with abdominal complaints or unexplained anemia.
A detailed history of non-steroidal anti-inflammatory use
and history of Helicobacter pylori infection should be
obtained prior to RT to assess risk factors for gastrointesti-
nal ulceration. Based upon the review of our patients'
records, we did not identify such risk factors, however. In
patients found to be at increased risk, we recommend pro-
longed acid suppression and eradication of Helicobacter
pylori if found. When corticosteroids are administered in
the early post-RT period, aggressive acid suppression
should be undertaken as well. Furthermore, biopsies
should be obtained at the time of endoscopy to rule out
an infectious etiology and to determine if foreign body
spherules or radiation changes are present.
Previous experiences [8] have shown a lower (3.8%) and
much higher (20%) [14] incidence of symptomatic gas-
troduodenal ulcerations. This lower complication rate
was reported to be a result of empiric coil embolization of
the gastroduodenal artery and all other collateral vessels
communicating with the gastrointestinal tract at the time
of angiography. In the first patient the short segment
between the left hepatic artery and the GDA may have
resulted in an easier retrograde reflux of microspheres into
the GDA resulting in shunting of microspheres to the gas-
trointestinal tract. The second patient had previously
received hepatic artery embolization resulting in small
sclerotic hepatic artery vasculature that may have contrib-
uted to impedance of forward flow of the microspheres
despite empiric GDA embolization. The anatomic variant
of the left hepatic artery arising from the left gastric artery
also may put the patient at risk for retrograde flow of the
microspheres. No risk factor for non-target flow was iden-
tified angiographically in the third patient pre-RT. Stagna-
tion of blood flow peri-procedurally likely contributed to
retrograde flow of the microspheres through the GDA.
While the routine embolization of the gastroduodenal
artery was not advocated by all at the time of our study
period, it has become common practice presently. Our
current practice is to selectively embolize the gastroduo-
denal artery and any vessel at risk for shunting to the gas-
trointestinal tract. In addition, we periodically re-verify
patency of the target vessel throughout the 90Y injection
process as stagnation of flow may result in redirection of
microspheres away from the hepatic circulation.
Furthermore, if 90Y microspheres are detected in biopsy
specimens, medical treatment including high dose proton
pump inhibitor therapy should be employed. Interven-
tional radiologic techniques are often successful, but the
optimal management strategy to treat gastrointestinal
hemorrhage as a complication of RT is unknown and an
early aggressive surgical approach to remove affected areas
should be considered if other methods have failed.
Conclusion
Gastrointestinal ulceration is a known and relatively com-
mon complication that is not often reported following 90Y
microsphere embolization with potentially life-threaten-
ing consequences. Since vague upper abdominal discom-
fort is common after RT and often not thoroughly
evaluated, the true incidence of occult ulceration is not
known but occurs in at least 11% of patients despite com-
prehensive pre-treatment angiographic evaluation when
empiric gastroduodenal artery embolization is not per-
formed.
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